4.7 Article

Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey

Journal

EUROPEAN HEART JOURNAL
Volume 43, Issue 29, Pages 2756-2766

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehac209

Keywords

Multiple valvular heart disease; Native valvular heart disease; Survival; Management; Cardiac surgery; Valvular Heart Disease II Survey

Funding

  1. Amgen
  2. AstraZeneca
  3. Bayer
  4. Boehringer Ingelheim
  5. Boston Scientific
  6. Bristol Myers Squibb
  7. Daiichi Sankyo Europe
  8. Eli Lilly and Company
  9. Edwards Lifesciences
  10. Gedeon Richter Plc
  11. Fondazione Internazionale Menarini
  12. Merck Sharpe and Dohme
  13. Novartis Pharma AG
  14. Novo Nordisk
  15. Pfizer
  16. ResMed
  17. Sanofi [20092018]
  18. Abbott Vascular International
  19. Pfizer Alliance
  20. Grupo Ferrer Inernacional
  21. Servier

Ask authors/readers for more resources

Patients with multiple native valvular heart disease are more common in women, have more severe heart failure and comorbidities, higher left atrial volumes and pulmonary pressures, lower survival rates, and higher rates of heart failure occurrence.
Aims To assess the characteristics, management, and survival of patients with multiple native valvular heart disease (VHD). Methods and results Among the 5087 patients with >= 1 severe left-sided native VHD included in the EURObservational VHD II Survey (maximum 3-month recruitment period per centre between January and August 2017 with a 6-month follow-up), 3571 had a single left-sided VHD (Group A, 70.2%), 363 had one severe left-sided VHD with moderate VHD of the other ipsilateral valve (Group B, 7.1%), and 1153 patients (22.7%) had >= 2 severe native VHDs (left-sided and/or tricuspid regurgitation, Group C). Patients with multiple VHD (Groups B and C) were more often women, had greater congestive heart failure (CHF) and comorbidity, higher left atrial volumes and pulmonary pressures, and lower ejection fraction than Group A patients (all P <= 0.01). During the index hospitalization, 36.7% of Group A (n = 1312), 26.7% of Group B (n = 97), and 32.7% of Group C (n = 377) underwent valvular intervention (P < 0.001). Six-month survival was better for Group A than for Group B or C (both P < 0.001), even after adjustment for age, sex, body mass index, and Charlson index [hazard ratio (HR) 95% confidence interval (CI) 1.62 (1.10-2.38) vs. Group B and HR 95% CI 1.72 (1.32-2.25) vs. Group C]. Groups B and C had more CHF at 6 months than Group A (both P < 0.001). Factors associated with mortality in Group C were age, CHF, and comorbidity (all P < 0.010). Conclusion Multiple VHD is common, encountered in nearly 30% of patients with left-sided native VHD, and associated with greater cardiac damage and leads to higher mortality and more heart failure at 6 months than single VHD, yet with lower rates of surgery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available